A Case of an Elderly Woman Who Developed Corneal Perforation in the Clinical Course of Myeloperoxidase Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

<div>Clinical course of AAV treatment and MPO-ANCA and C-reactive protein titer changes. After the surgery, methylprednisolone 500 mg pulse therapy was administered for three days, and 30 mg/day of oral PSL was started. Rituximab (500 mg) was then administered twice. The MPO-ANCA titer decreased to 10.0 U/mL. The patient was discharged after the PSL dose was reduced to 20 mg/day.</div>

Case Reports in Rheumatology

fig3

Figure 3

Figure 3: A Case of an Elderly Woman Who Developed Corneal Perforation in the Clinical Course of Myeloperoxidase Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 

Figure 3 | A Case of an Elderly Woman Who Developed Corneal Perforation in the Clinical Course of Myeloperoxidase Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 